MXPA04006458A - Pyrrolidone carboxamides. - Google Patents

Pyrrolidone carboxamides.

Info

Publication number
MXPA04006458A
MXPA04006458A MXPA04006458A MXPA04006458A MXPA04006458A MX PA04006458 A MXPA04006458 A MX PA04006458A MX PA04006458 A MXPA04006458 A MX PA04006458A MX PA04006458 A MXPA04006458 A MX PA04006458A MX PA04006458 A MXPA04006458 A MX PA04006458A
Authority
MX
Mexico
Prior art keywords
formula
pharmaceutically applicable
carboxamides
pyrrolidone
npy
Prior art date
Application number
MXPA04006458A
Other languages
Spanish (es)
Inventor
Valdenaire Oliver
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MXPA04006458A publication Critical patent/MXPA04006458A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)

Abstract

Pyrrolidone carboxamides of formula (I) where R2 = a group of formula (a) or (b), R5 = phenyl, heteroalkyl, aryloxy, alkoxy, alkanoyl or -NR6R7 and R1, X, R3, R4, R6 and R7 have the meanings given in the description and the claims, pharmaceutically applicable acid addition salts with basic compounds of formula (I), pharmaceutically applicable salts of acid compounds of formula (I) with bases, pharmaceutically applicable esters of hydroxy- or carboxy-group containing compounds of formula (I) and hydrates and solvates thereof, inhibit the interaction of neuropeptide Y (NPY) with one of the neuropeptide receptor subtypes (NPY-Y5) and are particularly suitable for the prevention and treatment of arthritis, diabetes and especially eating disorders and obesity. The above can be produced by known methods and converted into a galenic dosage form.
MXPA04006458A 2001-12-31 2002-12-27 Pyrrolidone carboxamides. MXPA04006458A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CH23812001 2001-12-31
CH0200429 2002-08-05
PCT/CH2002/000725 WO2003059905A1 (en) 2001-12-31 2002-12-27 Pyrrolidone carboxamides

Publications (1)

Publication Number Publication Date
MXPA04006458A true MXPA04006458A (en) 2004-10-04

Family

ID=25705687

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04006458A MXPA04006458A (en) 2001-12-31 2002-12-27 Pyrrolidone carboxamides.

Country Status (8)

Country Link
EP (1) EP1463724A1 (en)
JP (1) JP2005521651A (en)
KR (1) KR20040072697A (en)
CN (1) CN100534990C (en)
AU (1) AU2002350366A1 (en)
CA (1) CA2471620A1 (en)
MX (1) MXPA04006458A (en)
WO (1) WO2003059905A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0319151D0 (en) * 2003-08-14 2003-09-17 Glaxo Group Ltd Novel compounds
EP2305352A1 (en) 2004-04-02 2011-04-06 Merck Sharp & Dohme Corp. 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders
US20100222316A1 (en) 2004-04-29 2010-09-02 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US8415354B2 (en) 2004-04-29 2013-04-09 Abbott Laboratories Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US7880001B2 (en) 2004-04-29 2011-02-01 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US20090192198A1 (en) 2005-01-05 2009-07-30 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
AU2006204017B2 (en) 2005-01-05 2011-10-06 Abbvie Inc. Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
US8198331B2 (en) 2005-01-05 2012-06-12 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
US20090264650A1 (en) * 2005-03-31 2009-10-22 Nobuo Cho Prophylactic/Therapeutic Agent for Diabetes
JP4085129B2 (en) * 2005-08-09 2008-05-14 第一三共株式会社 New cercosporamide derivatives
JP4726243B2 (en) * 2005-08-09 2011-07-20 第一三共株式会社 New cercosporamide derivatives
US7435833B2 (en) 2006-04-07 2008-10-14 Abbott Laboratories Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme
JP5736098B2 (en) 2007-08-21 2015-06-17 アッヴィ・インコーポレイテッド Pharmaceutical composition for treating central nervous system disorders
GB0815781D0 (en) * 2008-08-29 2008-10-08 Xention Ltd Novel potassium channel blockers
EP2480531B1 (en) 2009-09-21 2014-11-05 ChemoCentryx, Inc. Pyrrolidinone carboxamide derivatives as chemerin-r (chemr23) modulators
CN102827056B (en) * 2012-09-03 2014-07-23 华东理工大学 N-aryl-substituted pyrrolidone derivative and application thereof
EP3126346B1 (en) * 2014-04-04 2018-07-11 Sanofi Substituted indanone compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
US10968176B2 (en) 2014-09-14 2021-04-06 Nanosynthons Llc Pyrrolidone derivatives, oligomers and polymers
US10420849B2 (en) * 2014-09-14 2019-09-24 Nanosynthons Llc Pyrrolidone derivatives, oligomers and polymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB856452A (en) * 1957-06-27 1960-12-14 Bayer Ag Protective agents against textile pests, mould and bacteria
US5281612A (en) * 1982-09-09 1994-01-25 Warner-Lambert Company Naphthyridine antibacterial agents
EP0393607B1 (en) * 1989-04-19 1996-02-21 Otsuka Pharmaceutical Co., Ltd. Phenylcarboxylic acid derivatives having a hetero ring
US6387932B1 (en) * 1999-06-25 2002-05-14 Merck & Co., Inc. Somatostatin agonists
AU6000900A (en) * 1999-07-23 2001-02-13 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
GB0010757D0 (en) * 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
CN100534990C (en) 2009-09-02
CN1610678A (en) 2005-04-27
AU2002350366A1 (en) 2003-07-30
WO2003059905A1 (en) 2003-07-24
EP1463724A1 (en) 2004-10-06
JP2005521651A (en) 2005-07-21
CA2471620A1 (en) 2003-07-24
KR20040072697A (en) 2004-08-18

Similar Documents

Publication Publication Date Title
MXPA04006458A (en) Pyrrolidone carboxamides.
GB0217757D0 (en) Novel compounds
GB0010188D0 (en) Inhibitors of dipeptidyl peptidase IV
WO2003037271A3 (en) Compounds, pharmaceutical compositions and methods of use therefor
EE200300403A (en) N-substituted Non-Aromatic Heterocyclic Compound, Pharmaceutical Composition Containing It, and Use of the Compound as a Pharmaceutical
PL1807072T3 (en) Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
LT2003017A (en) Polymorphs of an epothilone analog
MX2007005408A (en) Aminoquinazolines compounds.
GB0124933D0 (en) Chemical compounds
MXPA04002423A (en) Piperazine derivatives with ccr1 receptor antagonist activity.
MY134664A (en) 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipedemia
UA81624C2 (en) Tri-substituted heteroaryls and methods of making and using the same
NO20063230L (en) CRF receptor antagonists and methods for their preparation
MY121136A (en) Novel heterocyclic sulfonamides.
TNSN04136A1 (en) Aza-arylpiperazines
CA2499329A1 (en) Indole-3-carboxamides as glucokinase (gk) activators
GEP20074125B (en) Pyrazolopyridines and methods of making and using the same
PL1620425T3 (en) Substituted 3-cyanothiophene acetamides as glucagon receptor antagonists
MXPA03009750A (en) Chemical compounds.
MXPA04004263A (en) Hydrazono-malonitriles.
MY136632A (en) N-aryl piperidine substituted biphenylcarboxamides as inhibitors of apolipoprotein b secretion
WO2003066621A8 (en) Piperidine derivatives and their use as antagonists of tachykinins
WO2006008545A3 (en) Thiazole and isothiazole derivatives as protein kinase inhibitors
EP1786815A4 (en) Spiro compounds and methods for the modulation of chemokine receptor activity
DE60321888D1 (en)